LC/Q-TOF MS and LC/QQQ MS based bioanalysis of a new ferrocene derivative as a potential anticancer lead with promising drug-like characteristics
Copyright © 2022 Elsevier B.V. All rights reserved..
Pyrazolopyrimidine ring present in various approved drugs is reported to target the tyrosine kinase receptor. A new pyrazolopyrimidine ferrocene derivative, which targets tumor pyruvate kinase M2 showed an impressive antiproliferative profile against human oral squamous cell carcinoma cell line CAL27 assessed using Alamar blue assay. In line with the lead optimization process, the molecule was studied for physicochemical properties where a bioanalytical method has been developed in plasma on liquid chromatography-mass spectrometry and validated following the USFDA bioanalytical method validation guideline. Plasma stability and plasma protein binding potential of the molecule have been evaluated. All the major metabolites of the compound have been identified through in vitro metabolite study employing rat liver microsome, human liver microsome, and human S9 fractions. The in silico toxicity profile of the metabolites was assessed using ProTox II software. Log P, Log D, and pKa of the molecule were found to be 4.5, 5, and 12, respectively. The molecule was found to be quite stable in plasma and have a moderate affinity towards plasma proteins (about 75 % binding). Four major metabolites have been identified and characterized by UHPLCQ-TOF-MS. The metabolites were found to have a moderate safety profile. The validated bioanalytical method and the metabolic pathway will be useful for future clinical studies and to assess the safety profile of the molecule. The finding of this study may also be useful in analyzing the desired drug-like properties through bioanalysis while designing new chemical entities based on metallocenes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1210 |
|---|---|
| Enthalten in: |
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences - 1210(2022) vom: 01. Nov., Seite 123469 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jogpethe, Ashish [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.10.2022 Date Revised 18.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jchromb.2022.123469 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34653867X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34653867X | ||
| 003 | DE-627 | ||
| 005 | 20231226031712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jchromb.2022.123469 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM34653867X | ||
| 035 | |a (NLM)36137491 | ||
| 035 | |a (PII)S1570-0232(22)00373-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jogpethe, Ashish |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a LC/Q-TOF MS and LC/QQQ MS based bioanalysis of a new ferrocene derivative as a potential anticancer lead with promising drug-like characteristics |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2022 | ||
| 500 | |a Date Revised 18.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a Pyrazolopyrimidine ring present in various approved drugs is reported to target the tyrosine kinase receptor. A new pyrazolopyrimidine ferrocene derivative, which targets tumor pyruvate kinase M2 showed an impressive antiproliferative profile against human oral squamous cell carcinoma cell line CAL27 assessed using Alamar blue assay. In line with the lead optimization process, the molecule was studied for physicochemical properties where a bioanalytical method has been developed in plasma on liquid chromatography-mass spectrometry and validated following the USFDA bioanalytical method validation guideline. Plasma stability and plasma protein binding potential of the molecule have been evaluated. All the major metabolites of the compound have been identified through in vitro metabolite study employing rat liver microsome, human liver microsome, and human S9 fractions. The in silico toxicity profile of the metabolites was assessed using ProTox II software. Log P, Log D, and pKa of the molecule were found to be 4.5, 5, and 12, respectively. The molecule was found to be quite stable in plasma and have a moderate affinity towards plasma proteins (about 75 % binding). Four major metabolites have been identified and characterized by UHPLCQ-TOF-MS. The metabolites were found to have a moderate safety profile. The validated bioanalytical method and the metabolic pathway will be useful for future clinical studies and to assess the safety profile of the molecule. The finding of this study may also be useful in analyzing the desired drug-like properties through bioanalysis while designing new chemical entities based on metallocenes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiproliferative activity | |
| 650 | 4 | |a Bioanalysis | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Ferrocene based anticancer lead | |
| 650 | 4 | |a Metabolism pathway | |
| 650 | 4 | |a Physicochemical characterization | |
| 650 | 4 | |a Plasma protein binding | |
| 650 | 4 | |a Plasma stability | |
| 650 | 4 | |a Toxicity prediction | |
| 650 | 7 | |a Blood Proteins |2 NLM | |
| 650 | 7 | |a Ferrous Compounds |2 NLM | |
| 650 | 7 | |a Metallocenes |2 NLM | |
| 650 | 7 | |a Protoporphyrinogen Oxidase |2 NLM | |
| 650 | 7 | |a EC 1.3.3.4 |2 NLM | |
| 650 | 7 | |a Pyruvate Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.1.40 |2 NLM | |
| 650 | 7 | |a Receptor Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ferrocene |2 NLM | |
| 650 | 7 | |a U96PKG90JQ |2 NLM | |
| 700 | 1 | |a Jadav, Tarang |e verfasserin |4 aut | |
| 700 | 1 | |a Rajput, Niraj |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar Sahu, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Rudradip |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Astha |e verfasserin |4 aut | |
| 700 | 1 | |a Shard, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Sengupta, Pinaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of chromatography. B, Analytical technologies in the biomedical and life sciences |d 2002 |g 1210(2022) vom: 01. Nov., Seite 123469 |w (DE-627)NLM117075906 |x 1873-376X |7 nnns |
| 773 | 1 | 8 | |g volume:1210 |g year:2022 |g day:01 |g month:11 |g pages:123469 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jchromb.2022.123469 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1210 |j 2022 |b 01 |c 11 |h 123469 | ||